Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies.

Autor: Roeker LE; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Coombs CC; Department of Medicine, University of California Irvine Health, Orange, California, USA., Shah NN; Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Jurczak W; Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland., Woyach JA; The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA., Cheah CY; Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Washington, Australia., Patel K; Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Seattle, Washington, USA., Maddocks K; The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA., Wang Y; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA., Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna, Italy.; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy., Munir T; Department of Haematology, St. James's University Hospital, Leeds, UK., Koh Y; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea., Thompson MC; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Muehlenbein CE; Loxo@Lilly, Indianapolis, Indiana, USA., Wang C; Eli Lilly and Company, Indianapolis, Indiana, USA., Sizelove R; Eli Lilly and Company, Indianapolis, Indiana, USA., Abhyankar S; Eli Lilly and Company, Indianapolis, Indiana, USA., Hasanabba S; Eli Lilly and Company, Indianapolis, Indiana, USA., Tsai DE; Loxo@Lilly, Indianapolis, Indiana, USA., Eyre TA; Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, UK., Wang M; MD Anderson Cancer Center, Houston, Texas, USA.

Publikováno v: Acta haematologica [Acta Haematol] 2024 Jun 05, pp. 1-17. Date of Electronic Publication: 2024 Jun 05.